,sentence,pubmed_id,content,label,labeler
0,"19 ||| Introduction ||| 1.19 ||| Population and treatment VALUE included patients 50 years or older, with treated or untreated hypertension at baseline and predefined combinations of cardiovascular risk factors and cardiovascular disease.",15207952,50 years or older,po.Age,HeYingzhi
1,"19 ||| Introduction ||| 1.19 ||| Population and treatment VALUE included patients 50 years or older, with treated or untreated hypertension at baseline and predefined combinations of cardiovascular risk factors and cardiovascular disease.",15207952,treated or untreated hypertension,po.Disease,HeYingzhi
2,"30 ||| Introduction ||| 1.30 ||| Valsartanbased regimen 18 The qualifying risk factors were male sex, age older than 50 years, verified diabetes mellitus, current smoking, high total cholesterol, left ventricular hypertrophy by electrocardiogram, proteinuria on dipstick and raised serum creatinine between 150 and 265 ␮mol/L (if >265 ␮mol/L patients were judged to have severe renal failure and were excluded).",15207952,serum creatinine between 150 and 265 ␮mol/L (if >265 ␮mol/L patients were judged to have severe renal failure and were excluded),po.Disease,HeYingzhi
3,"20 ||| Introduction ||| 1.20 ||| Additional inclusion criteria were: men or women of any racial background, 50 years of age and older, and presence of cardiovascular risk factors or disease according to an algorithm based on age and sex.",15207952,"Additional inclusion criteria were: men or women of any racial background, 50 years of age and older, and presence of cardiovascular risk factors or disease according to an algorithm based on age and sex",po.Disease,HeYingzhi
4,"41 ||| Introduction ||| 1.41 ||| Patients already receiving antihypertensive treatment discontinued taking previous drugs and were directly rolled over to one of the two VALUE arms starting with either valsartan 80 mg or amlodipine 5 mg, without a placebo run-in period (figure 1).",15207952,"Patients already receiving antihypertensive treatment discontinued taking previous drugs and were directly rolled over to one of the two VALUE arms starting with either valsartan 80 mg or amlodipine 5 mg, without a placebo run-in period",i.Procedure,HeYingzhi
5,97 ||| Statistical methods ||| 3.11 ||| The median daily doses were 151·7 mg (IQR 83·2-158·5) for valsartan and 8·5 mg (IQR 5·0-9·9) for amlodipine.,15207952,The median daily doses were 151·7 mg (IQR 83·2-158·5) for valsartan and 8·5 mg (IQR 5·0-9·9) for amlodipine.,i.Procedure,HeYingzhi
6,"98 ||| Statistical methods ||| 3.12 ||| When study drug interruptions were included, the median doses were 149·3 mg (80·2-158·5) and 8·2 mg (5·0-9·9), respectively.",15207952,"When study drug interruptions were included, the median doses were 149·3 mg (80·2-158·5) and 8·2 mg (5·0-9·9), respectively.",i.Procedure,HeYingzhi
7,"142 ||| Discussion ||| 4.21 ||| Finally, recent findings showed no difference in coronary heart disease between angiotensin-receptor blockers 16,24 and comparator groups.",15207952,"no difference in coronary heart disease between angiotensin-receptor blockers 16,24 and comparator groups.",o.Patient,HeYingzhi
8,"173 ||| Discussion ||| 4.52 ||| A similar reduction was seen with lisinopril compared with amlodipine in ALLHAT, 10 suggesting that this effect might be related to blockade of biological effects of angiotensin II.",15207952,A similar reduction was seen with lisinopril compared with amlodipine in ALLHAT,o.Treatment,HeYingzhi
